Itoh Takashi, Uzuki Miwa, Shimamura Tadashi, Sawai Takashi
Department of 1st Pathology, Department of Orthopedic Surgery, School of Medicine, Iwate Medical University, Morioka-city.
Ryumachi. 2002 Feb;42(1):60-9.
Matrix metalloproteinase (MMP) is a novel proteolytic enzyme that plays an important role in joint destruction in rheumatoid arthritis (RA). To elucidate the dynamics of MMPs in serum and synovial fluid, we measured the concentration and activity of MMP-1, -9, -13 in serum and synovial fluid of RA patients. Among them especially we focused on newly defined MMP-13 and compared with MMP-1 and MMP-9.
Serum, synovial fluid and synovial, and pannus tissues used in this study were obtained from RA patients. To compare the dynamics of each enzymic protein, we performed the following procedures: Firstly, we measured concentration of MMP-1, -9, -13 by using ELISA kit. Secondly, the activity of MMP-1, -9, -13 were also measured by using the MMP activity assay system. Then we obtained the activity ratio of each MMP from calculation of activity/concentration. We also examined the expression of MMP-13 in synovial tissues by immunohistochemical and in situ hybridization studies.
Concentration and activity levels of MMP-1, -9, -13 were significantly higher in RA serum and synovial fluid than in OA. Activity ratio of MMP-1, MMP-9 MMP-13 were 3.60 +/- 1.56, 1.03 +/- 1.75, 35.30 +/- 24.28 (ODA450/ng) in RA serum and 1.60 +/- 2.02, 3.97 +/- 14.83, 14.25 +/- 15.04 (ODA450/ng) in synovial fluid. In synovial and pannus tissues. MMP-13 positive cells were diffusely demonstrated by immunohistochemical and in situ hybridization studies. They were synovial lining cells, endothelial cells, fibroblasts, monocytes, osteoblasts, and chondrocytes.
MMP-13 positive cells were diffusely presented in joint regions including synovial and pannus tissues. Although the concentration of MMP-13 was not so high, its activity ratio was elevated in serum and synovial fluid in the patients with rheumatoid arthritis.
基质金属蛋白酶(MMP)是一种新型蛋白水解酶,在类风湿关节炎(RA)的关节破坏中起重要作用。为阐明MMPs在血清和滑液中的动态变化,我们检测了RA患者血清和滑液中MMP-1、-9、-13的浓度和活性。其中我们特别关注新定义的MMP-13,并与MMP-1和MMP-9进行比较。
本研究中使用的血清、滑液、滑膜和血管翳组织取自RA患者。为比较每种酶蛋白的动态变化,我们进行了以下操作:首先,使用ELISA试剂盒检测MMP-1、-9、-13的浓度。其次,使用MMP活性检测系统检测MMP-1、-9、-13的活性。然后通过活性/浓度计算得出每种MMP的活性比值。我们还通过免疫组织化学和原位杂交研究检测了滑膜组织中MMP-13的表达。
RA血清和滑液中MMP-1、-9、-13的浓度和活性水平显著高于骨关节炎(OA)。RA血清中MMP-1、MMP-9、MMP-13的活性比值分别为3.60±1.56、1.03±1.75、35.30±24.28(ODA450/ng),滑液中分别为1.60±[此处原文似乎有误,应为2.02]、3.97±14.83、14.25±15.04(ODA450/ng)。在滑膜和血管翳组织中,免疫组织化学和原位杂交研究显示MMP-13阳性细胞呈弥漫性分布。它们是滑膜衬里细胞、内皮细胞、成纤维细胞、单核细胞、成骨细胞和软骨细胞。
MMP-13阳性细胞弥漫性存在于包括滑膜和血管翳组织在内的关节区域。虽然MMP-13的浓度不高,但其活性比值在类风湿关节炎患者的血清和滑液中升高。